• LAST PRICE
    10.5700
  • TODAY'S CHANGE (%)
    Trending Down-0.1500 (-1.3993%)
  • Bid / Lots
    9.6500/ 1
  • Ask / Lots
    11.3500/ 1
  • Open / Previous Close
    10.7200 / 10.7200
  • Day Range
    Low 10.2436
    High 10.9997
  • 52 Week Range
    Low 4.8100
    High 14.4020
  • Volume
    102,900
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 10.72
TimeVolumeCELC
09:32 ET52810.51
09:33 ET10010.99
09:39 ET10010.99
09:46 ET10010.56
10:04 ET10010.52
10:06 ET10010.52
10:11 ET10010.75
10:18 ET30010.55
10:20 ET150010.54
10:22 ET20010.96
10:24 ET40010.7
10:26 ET40010.53
10:27 ET20010.65
10:29 ET70010.62
10:31 ET40010.6
10:33 ET40010.53
10:36 ET30010.6
10:38 ET140010.8
10:40 ET130010.53
10:42 ET30010.52
10:44 ET10010.58
10:45 ET20010.53
10:47 ET60010.52
10:49 ET70010.52
10:51 ET149010.5
10:54 ET10010.35
10:56 ET634710.42
10:58 ET37810.5125
11:05 ET10010.59
11:07 ET10010.595
11:14 ET40010.5897
11:16 ET30010.5897
11:21 ET30010.59
11:23 ET20010.5897
11:25 ET17310.59
11:30 ET20010.7097
11:32 ET20010.65
11:34 ET20010.7099
11:36 ET21010.71
11:38 ET40010.9797
11:39 ET140010.7498
11:41 ET70010.9797
11:43 ET20010.9
11:45 ET250010.86
11:48 ET140010.81
11:50 ET112710.81
11:52 ET70010.81
11:54 ET210010.7
11:56 ET20010.59
11:57 ET70010.6907
11:59 ET20010.59
12:01 ET20010.6715
12:21 ET10010.8
12:24 ET20010.8
12:26 ET10010.8
12:28 ET60010.6598
12:32 ET100010.63
12:35 ET20010.7197
12:37 ET30010.7
12:39 ET30010.9997
12:42 ET60010.7698
12:44 ET120010.6
12:46 ET120010.8
12:48 ET100010.6
12:50 ET120010.78
12:51 ET130010.8
12:53 ET40010.72
12:55 ET50010.73
12:57 ET20010.61
01:00 ET10010.61
01:02 ET10010.7
01:04 ET10010.61
01:09 ET10010.71
01:11 ET10010.69
01:33 ET10010.89
01:36 ET10010.89
01:38 ET10010.89
01:40 ET10010.89
01:42 ET10010.88
01:44 ET20010.8697
01:45 ET80010.7198
01:47 ET20010.8697
01:49 ET40010.8597
01:51 ET50010.82
01:54 ET50010.82
01:56 ET76810.71
01:58 ET20010.8597
02:00 ET20010.8597
02:02 ET130010.795
02:03 ET50010.795
02:05 ET100010.76
02:07 ET30010.68
02:09 ET100010.76
02:12 ET50010.7
02:14 ET50010.7505
02:16 ET40010.69
02:18 ET50010.66
02:20 ET90010.65
02:25 ET10010.69
02:34 ET10010.6
02:36 ET60010.66
02:38 ET40010.67
02:39 ET30010.63
02:41 ET90010.6
02:45 ET20010.63
02:48 ET20010.6
02:50 ET22010.5955
02:52 ET20010.53
02:54 ET160010.63
02:56 ET30010.58
02:57 ET32110.66
02:59 ET20010.62
03:01 ET10010.62
03:03 ET20010.65
03:08 ET20010.59
03:10 ET10010.65
03:12 ET60010.61
03:14 ET40010.61
03:15 ET10010.65
03:17 ET20010.59
03:19 ET30010.59
03:21 ET30010.59
03:24 ET40010.57
03:26 ET10010.64
03:28 ET60010.64
03:30 ET70010.58
03:32 ET60010.58
03:33 ET140010.58
03:35 ET10010.63
03:39 ET102010.62
03:42 ET20010.6
03:44 ET10010.65
03:46 ET33310.69
03:48 ET100010.7099
03:50 ET50010.655
03:51 ET110010.7899
03:53 ET100010.65
03:55 ET150010.78
03:57 ET162310.695
04:00 ET386410.57
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCELC
Celcuity Inc
232.3M
-4.4x
---
United StatesNAUT
Nautilus Biotechnology Inc
234.5M
-4.0x
---
United StatesABOS
Acumen Pharmaceuticals Inc
240.2M
-4.8x
---
United StatesGLSI
Greenwich Lifesciences Inc
244.6M
-33.6x
---
United StatesPRAX
Praxis Precision Medicines Inc
219.6M
-0.9x
---
United StatesCYDY
Cytodyn Inc
247.0M
-1.0x
---
As of 2023-01-26

Company Information

Celcuity, Inc. is a clinical-stage biotechnology company. The Company is seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. Its therapeutic efforts are focused on developing molecularly targeted therapies that address the same cancer driver a CELsignia companion diagnostic can identify. The Company's lead therapeutic candidate is gedatolisib, a potent, reversible dual inhibitor that selectively targets all Class I isoforms of PI3K and mammalian target of rapamycin (mTOR). Its mechanism of action and pharmacokinetic properties are highly differentiated from other investigational therapies that target PI3K or mTOR alone or together. Its initial clinical development program for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), HER2-negative, advanced, or metastatic breast cancer. The Company's additional clinical development programs focus on various other tumor types.

Contact Information

Headquarters
16305 36th Ave N Ste 100MINNEAPOLIS, MN, United States 55446-4285
Phone
763-392-0767
Fax
302-655-5049

Executives

Chairman of the Board, Chief Executive Officer, Co-Founder
Brian Sullivan
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Lance Laing
Chief Financial Officer
Vicky Hahne
Independent Director
Richard Buller
Independent Director
David Dalvey

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$232.3M
Revenue (TTM)
$0.00
Shares Outstanding
21.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.72
EPS
$-2.38
Book Value
$4.61
P/E Ratio
-4.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.